Cullinan REZILIENT3 Zipalertinib NSCLC Data Event
Analysis based on 7 articles · First reported Sep 10, 2026 · Last updated Sep 14, 2026
Positive interim Phase 3 data for zipalertinib plus chemotherapy in EGFR exon 20 insertion NSCLC could support Cullinan Therapeutics pipeline value and investor confidence, potentially lifting CGEM shares. The event is company-specific and unlikely to move broader biotech or pharmaceutical indices materially.
Cullinan Therapeutics announced that it will host a virtual event for analysts and institutional investors on September 14, 2026, at 8:00 a.m. ET to discuss results from the planned interim analysis of the Phase 3 REZILIENT3 trial of zipalertinib plus chemotherapy in first-line EGFR exon 20 insertion mutation-positive non-small cell lung cancer (NSCLC). The interim analysis results were presented in Presidential Symposium 2 on September 13, 2026, at the International Association for the Study of Lung Cancer 2026 World Conference on Lung Cancer (WCLC), held September 12-15, 2026 in Seoul, South Korea. The trial previously met its primary endpoint of progression-free survival at the planned interim analysis. The virtual event features Nadim Ahmed, Chief Executive Officer, and Jeffrey Jones, MD, MBA, Chief Medical Officer, with a live webcast and archived replay available on the company investor relations website.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard